• Breast cancer brain metastases (BCBM) remain a challenging consequence of advanced breast cancer (ABC).

• It is estimated that the incidence of brain metastases in untreated patients with metastatic breast cancer is as high as 30%.

• Treatment options for patients with brain metastases following prior surgery and/or radiation therapy remains limited.

• There is no standard treatment that has been shown to improve survival for patients with previously treated central nervous system (CNS) metastases.

• There is no standard treatment that has been shown to improve survival for patients with previously treated central nervous system (CNS) metastases.

• The randomized Phase 3 BEACON trial compared etirinotecan pegol (EP) vs TPC (eribulin, ixabepilone, or nab-paclitaxel).

• The blood-brain barrier prevents many chemotherapeutic agents used in treatment from reaching effective concentrations in brain metastases.

• Currrently no cytotoxic or molecularly targeted agents are approved for the treatment or prevention of breast cancer brain metastases.